Results 1 to 10 of about 32,331,402 (154)

Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutS homolog 2 in resected esophageal squamous cell carcinoma [PDF]

Journal of Thoracic and Cardiovascular Surgery, 2005
Aberrant expression of mismatch repair genes, such as human mutL homolog 1 (hMLH1) and human mutS homolog 2 (hMSH2), are common in some human cancers, and promoter methylation is believed to inactivate expression of hMLH1. We investigated whether promoter methylation is involved in loss of hMLH1 protein and whether aberrant expression of hMLH1 and ...
Ho-Jui Tung, Yi-Ching Wang, Shih-Chun Lee   +2 more
exaly   +5 more sources

The GHKL ATPase Family as a Paradigm for MutL Homolog Function in DNA Mismatch Repair [PDF]

International Journal of Molecular Sciences
ATP hydrolysis drives essential processes across biology, from nucleic acid translocation and conformational switching to signal transduction. The GHKL ATPase family—DNA Gyrase B, Heat Shock Protein 90 (Hsp90), Histidine Kinases, and MutL homologs ...
Carol Manhart
exaly   +3 more sources

Human Epidermal Growth Factor Receptor 2-Positive, Claudin-18 Isoform 2-Positive, Mismatch Repair-Deficient Gastric Cancer Revealed by Immunohistochemical Analysis of Surgical Specimens: A Case Report. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Human epidermal growth factor receptor 2 (HER2), mismatch repair (MMR) proteins, claudin‐18 isoform 2 (CLDN18.2), and the programmed cell death ligand‐1 combined positive score (PD‐L1 CPS) are predictive biomarkers for the efficacy of combination chemotherapy in patients with locally advanced unresectable or metastatic gastric or ...
Takagi D, Mori M, Shuto K, Kosugi C, Usui A, Takayanagi R, Sato S, Adachi S, Fujino T, Yamazaki K, Shimizu H.   +10 more
europepmc   +2 more sources

The expression of Mutl Protein Homolog 1 (MLH1) and Muts Homolog 2 (MSH2) in colorectal carcinoma: An immunohistochemical study

Indian Journal of Pathology and Microbiology
Background: The development of colorectal carcinoma is a complicated multistep process that involves the accumulation of mutations in tumor suppressor genes and oncogenes.
Eshita Garg, Manisha Sharma, Manas Madan, Gurleen Kaur, Karamjit S Gill, Ishaan Khanna   +5 more
doaj   +3 more sources

Mechanisms That Govern Recombinase Fidelity Control During Eukaryotic Homologous Recombination. [PDF]

Bioessays
The rate of recombinase filament formation controls the fidelity of the homologous recombination reaction by either restricting the length of strand pairing for high‐fidelity repair or increasing the length of strand pairing for more complex outcomes.
Korkmaz I, Crickard JB.
europepmc   +2 more sources

Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab [PDF]

ESMO Gastrointestinal Oncology
Background: Immune checkpoint inhibitors (ICIs) are standard treatment for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) gastrointestinal tumors but resistance remains relevant.
N. Martínez Lago, M. Sánchez Ares, A. Carral Maseda, M. Pérez Martelo, M. Covela Rúa, A. Fernández Montes, J. de la Cámara Gómez, P. González Villarroel, M. Reboredo López, M.E. Padín Iruegas, I. Abdulkader Nallib   +10 more
doaj   +2 more sources

The economic value of mismatch repair–guided immunotherapy in endometrial cancer: companion testing and patient selection [PDF]

Frontiers in Medicine
Mismatch repair (MMR) status has moved from hereditary-cancer screening to a central predictive biomarker for immunotherapy in endometrial cancer. The marked difference in treatment benefit between MMR-deficient/microsatellite instability-high (dMMR/MSI ...
Sihan Jing, Yuan He, Yuan He, Yang Liu
doaj   +2 more sources

Exome Sequencing Identifies Variants in MLH1 and ERBB2 as Potential Cancer-Predisposing Factors in Familial Early-Onset Colorectal Cancer. [PDF]

Kaohsiung J Med Sci
ABSTRACT Colorectal cancer (CRC) has raised considerable health concerns worldwide, with increasing incidence rates, specifically among younger populations. Despite remarkable progress in diagnosing and treating various diseases, the genetic basis of CRC remains only partially understood.
Bagheri B, Mohsen-Pour N, Salehi N, Moghadam PK, Zeinalpour A, Sadeghi A, Kalayinia S, Fatemi N.   +7 more
europepmc   +2 more sources

The CtIP-CtBP1/2-HDAC1-AP1 transcriptional complex is required for the transrepression of DNA damage modulators in the pathogenesis of osteosarcoma

Translational Oncology, 2022
Most tumors, including osteosarcomas, have deficiencies in DNA damage repair. However, the regulatory mechanisms underlying dysregulation of DNA damage repair genes are still being investigated.
Xun Chen, Qian Zhang, Xiaoqian Dang, Jinzhu Fan, Tao Song, Zhong Li, Ning Duan, Wentao Zhang   +7 more
doaj   +1 more source

Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma

Scientific Reports, 2022
The methylation status of the O6-methylguanine methyltransferase (MGMT) gene promoter has been widely accepted as a prognostic biomarker for treatment with the alkylator, temozolomide (TMZ). In the absence of promoter methylation, the MGMT enzyme removes
Sachita Ganesa, Amrita Sule, Ranjini K. Sundaram, Ranjit S. Bindra   +3 more
doaj   +1 more source